Search Results 291-300 of 7904 for SC

  1. Publications - Mark D. Tyson, II, M.D., M.P.H. - Mayo Clinic

    Briggs LG, Parke SC, Beck KL, Sinha D, Gill V, Van Ligten MJ, Bain PA, Tyson MD 2nd, Abdul-Muhsin HM, Quillen JK, Dodoo CA, De Luigi AJ, Branstiter NL, Trinh QD ...

  2. Publications - Shannon M. Dunlay, M.D., M.S. - Mayo Clinic

    ... SC, Habermann EB. Effect of hospital-at-home vs. traditional brick-and-mortar hospital care in acutely ill adults: study protocol for a pragmatic randomized ...

  3. Knee Arthritis Clinical Trials

    The purpose of this study is to determine the safety of sc-rAAV2.5IL-1Ra, a gene therapy carried by a virus and delivered by injection into the knee joint of ...

  4. Multisystem inflammatory syndrome in children (MIS-C) and COVID-19 - Diagnosis and treatment - Mayo Clinic

    Aronoff SC, et al. The natural history of severe acute respiratory syndrome coronavirus 2-related multisystem inflammatory syndrome in children (MIS-C): A ...

  5. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely ...

  6. Diseases and Conditions that Start with A - Mayo Clinic

    Browse a comprehensive list of medical diseases and conditions that start with the letter A from the experts at Mayo Clinic.

  7. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... SC dose at Week 2 [or one 80 mg SC dose at Baseline, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]); OR; At ...

  8. Evanthia Galanis, M.D. - Mayo Clinic Faculty Profiles

    D.Sc - ""Development and application of quantitative immunoenzymatic assays (ELISAS) and immunoblotting techniques in the study of specificity and title of ...

  9. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    MTX: ≥ 15 mg/week subcutaneous (SC) or intramuscular (IM); ... At least one 4-week induction regimen of golimumab (200 mg SC at Week 0 and 100 mg SC at Week 2); ...

  10. Renal artery stenosis - Diagnosis and treatment - Mayo Clinic

    Textor SC, et al. The role of hypoxia in ischemic chronic kidney disease. Seminars in Nephrology. 2019; doi:10.1016/j.semnephrol.2019.10.008. Textor SC.